Immunai wants to digitally map the immune system, and it’s amplified those efforts in recent months with two acquisitions and multiple funding rounds. The latest is a $215 million series B that will fund new partnerships, more acquisitions and a doubling of the team.
The New York City-based startup, founded in 2018, hauled in the financing after already raising $60 million in February and a $20 million seed round last year. The fresh proceeds come after two acquisitions this year: single-cell genomics software firm Dropprint Genomics in March and Swiss bioinformatics company Nebion in July.
Those acquisitions and Wednesday’s financing are geared toward elevating Immunai to the “largest single-cell immune database in the world,” said Noam Solomon, Ph.D., CEO and co-founder, in an interview with Fierce Biotech.